How would you treat a patient with Gleason 8 or 9 prostate cancer, pretreatment PSA 15-24, with retroperitoneal adenopathy?  

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as castrate sensitive metastatic disease without biopsy confirmation?



Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Radiation Oncologist at Highlands Oncology Group
Agree. I would boost the node up to the same dose ...
Medical Oncologist at Saint Vincent Cancer and Wellness Center
Thank you. 
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice